Recent Updates
Recently added Catalysts

IgA Nephropathy: 4 biotech companies with clinical-stage programmes

Immunology & InflammationConcentrated betData as of 2026-09-04

Competitors4in the clinic
Median market cap$1.8Buniverse median $1.20B
Allocated capital$3.6B$6.6B competing
Phase 3 or filed22 mid, 0 early
Pure plays1this indication only
Capital rank52/299crowding rank 49

IgA Nephropathy is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $1.8B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

2 of the 4 are in Phase 3 or filed, and 4 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$3.6B of allocated capital sits in IgA Nephropathy, 52nd of 299 indications, and 1 of the 4 companies are pure plays that trade on this indication alone.

Companies developing drugs for IgA Nephropathy 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
VERAVera TherapeuticsAtaciceptPhase 33$2.5BYes1 30 Sep 2026
BHVNBiohavenBHV-1400Phase 32$2.4BNo7 23 Oct 2026
JBIOJade BiosciencesJADE101Phase 21$1.3BNo2 30 Sep 2026
QTTBQ32 BioADX-097Phase 21$381MNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. VERA holds 38% of the $6.6B competing in this indication.

Why IgA Nephropathy is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. IgA Nephropathy has 4 competitors and a median of $1.8B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Thyroid Eye Disease2 companies · $3.6B · median $2.8BConcentrated betSjögren's Disease4 companies · $4.4B · median $1.7BConcentrated betWarm Autoimmune Hemolytic Anemia2 companies · $2.4B · median $3.8BConcentrated betAlopecia Areata3 companies · $2.2B · median $1.6BConcentrated betWrinkles1 company · $2.2B · median $11.0BUncontestedPrimary Biliary Cholangitis1 company · $2.2B · median $6.5BUncontestedPrimary Sclerosing Cholangitis1 company · $2.2B · median $6.5BUncontestedCrohn's Disease4 companies · $5.1B · median $714MOrphan corner

IgA Nephropathy pipeline questions

Which biotech companies are developing drugs for IgA Nephropathy?

Vera Therapeutics (VERA, Atacicept, Phase 3); Biohaven (BHVN, BHV-1400, Phase 3); Jade Biosciences (JBIO, JADE101, Phase 2); Q32 Bio (QTTB, ADX-097, Phase 2). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in IgA Nephropathy.

How advanced is the IgA Nephropathy pipeline?

Of the 4 clinical-stage programmes in IgA Nephropathy, 2 are in Phase 3 or filed, 2 are in mid-stage development and 0 are in early-stage development.

How much is the typical IgA Nephropathy biotech company worth?

The median company developing a drug for IgA Nephropathy is worth $1.8B, against a median of $1.20B across the whole universe. $3.6B of allocated capital sits in the indication, ranking it 52nd of 299.

When is the next IgA Nephropathy catalyst?

The next dated catalyst in IgA Nephropathy is VERA on 30 Sep 2026. 4 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map